Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
J Perinat Med ; 52(2): 119-125, 2024 Feb 26.
Article in English | MEDLINE | ID: mdl-38059494

ABSTRACT

OBJECTIVES: Mechanical ventilation in prematurely born infants, particularly if prolonged, can cause long term complications including bronchopulmonary dysplasia. Timely extubation then is essential, yet predicting its success remains challenging. Artificial intelligence (AI) may provide a potential solution. CONTENT: A narrative review was undertaken to explore AI's role in predicting extubation success in prematurely born infants. Across the 11 studies analysed, the range of reported area under the receiver operator characteristic curve (AUC) for the selected prediction models was between 0.7 and 0.87. Only two studies implemented an external validation procedure. Comparison to the results of clinical predictors was made in two studies. One group reported a logistic regression model that outperformed clinical predictors on decision tree analysis, while another group reported clinical predictors outperformed their artificial neural network model (AUCs: ANN 0.68 vs. clinical predictors 0.86). Amongst the studies there was an heterogenous selection of variables for inclusion in prediction models, as well as variations in definitions of extubation failure. SUMMARY: Although there is potential for AI to enhance extubation success, no model's performance has yet surpassed that of clinical predictors. OUTLOOK: Future studies should incorporate external validation to increase the applicability of the models to clinical settings.


Subject(s)
Artificial Intelligence , Intensive Care Units, Neonatal , Humans , Infant, Newborn , Infant , Airway Extubation/adverse effects , Respiration, Artificial/adverse effects , Forecasting
3.
Acta Paediatr ; 112(12): 2503-2506, 2023 12.
Article in English | MEDLINE | ID: mdl-37675620

ABSTRACT

AIM: To perform a survey on postnatal corticosteroids usage in neonatal units in the United Kingdom and Ireland. METHODS: An 18-item structured questionnaire was created asking for the level of neonatal care and corticosteroid prescribing practices. A consultant neonatologist or senor specialty training registrar/advanced neonatal nurse practitioner was contacted in every neonatal unit in the UK and Ireland between September and December 2022. RESULTS: The response rate to the survey was 96% (203 of 211 units). Postnatal corticosteroids were prescribed in 48% of units: 5% of special care units, 43% of local neonatal units and 100% of neonatal intensive care units. Most units (90%) prescribed dexamethasone, which was prescribed to infants born at gestational ages less than 30 weeks in all those units prescribing postnatal corticosteroids, however, eight units also reported use in infants greater than 30 weeks of gestation. Dexamethasone regimens varied with starting doses from 50 to 500 µg/kg/day. Most tertiary units (97%) prescribed repeated courses of dexamethasone. In all levels of neonatal care, postnatal corticosteroids were prescribed to ventilated infants as well as those receiving non-invasive respiratory support. CONCLUSION: There is use of postnatal corticosteroids in all levels of neonatal care and much of the practice is not evidence based.


Subject(s)
Bronchopulmonary Dysplasia , Glucocorticoids , Infant, Newborn , Infant , Humans , Dexamethasone/therapeutic use , Ireland , Adrenal Cortex Hormones/therapeutic use , United Kingdom , Intensive Care Units, Neonatal
4.
J Perinat Med ; 51(9): 1120-1128, 2023 Nov 27.
Article in English | MEDLINE | ID: mdl-37606507

ABSTRACT

BACKGROUND: Dexamethasone administration can reduce bronchopulmonary dysplasia, our objective was to identify long term adverse effects. CONTENT: A systematic review was performed to determine the childhood and adolescent cardiopulmonary and cognitive effects of dexamethasone systemically administered to preterm infants during neonatal intensive care. Relevant studies were identified by searching two electronic health databases and the grey literature. Spirometry assessments were used as respiratory outcomes, blood pressure and echocardiography assessments as cardiovascular outcomes and cognitive and motor function as cognitive outcomes. From 1,479 articles initially identified, 18 studies (overall 1,609 patients) were included (respiratory n=8, cardiovascular n=2, cognitive n=10); all were observational cohort studies. Dexamethasone exposure was associated with worse pulmonary outcomes in children and adolescents (more abnormal FVC and FEV1:FVC z scores). Dexamethasone exposure was associated in one study with lower IQ scores compared to preterm controls (mean 78.2 [SD 15.0] vs. 84.4 [12.6], [p=0.008]) and in two others was associated with lower total and performance IQ when compared to term controls (p<0.001). SUMMARY AND OUTLOOK: Postnatal dexamethasone exposure has a negative influence on pulmonary and cognitive outcomes in childhood and adolescence. Medications with a better benefit to risk profile need to be identified.


Subject(s)
Bronchopulmonary Dysplasia , Dexamethasone , Glucocorticoids , Adolescent , Child , Humans , Infant , Infant, Newborn , Adrenal Cortex Hormones/adverse effects , Anti-Inflammatory Agents/therapeutic use , Bronchopulmonary Dysplasia/prevention & control , Bronchopulmonary Dysplasia/drug therapy , Chronic Disease , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Glucocorticoids/therapeutic use , Infant, Premature
6.
Nephron ; 139(1): 63-69, 2018.
Article in English | MEDLINE | ID: mdl-29402819

ABSTRACT

BACKGROUND: IgA nephropathy is the most common primary glomerulonephritis worldwide and a significant cause of end-stage renal disease (ESRD). While most cases of IgA nephropathy are considered sporadic, familial cases have been reported. METHODS: We performed a national audit of 1,809 patients attending renal clinics and dialysis units to identify a family history among patients with kidney disease. We reviewed all renal biopsies performed at our institution spanning a 30-year period. Paediatric cases were not included. RESULTS: We identified 14 families involving 41 affected individuals with biopsy-proven IgA nephropathy and at least one other member with either biopsy-proven IgA nephropathy or ESRD. Detailed family histories were obtained, medical records reviewed and family pedigrees constructed. Retrospective application of the MESTC criteria to all familial IgA biopsies was performed. Seven families had 2 or more members with biopsy-proven IgA nephropathy, equating to 23 (1.8%) of 1,283 biopsies with IgA nephropathy over the last 30 years. A complex inheritance pattern was observed, with autosomal dominant and autosomal recessive families identified with varying penetrance. There was a male preponderance (68%), and a complex heterogeneity in the clinical and histopathological features of familial IgA patients (age range 16-60 years; creatinine range 60-350 µmol/L). We observed a high rate (66%) of progression to ESRD, with a mean time to progression of 5.13 years (SD 1.8 years; range 2-8 years). Among those patients who had undergone transplantation, recurrence of disease was reported in 5 (50%) cases. CONCLUSION: These data suggests familial aggregation of IgA nephropathy, confirm the clinical and histopathological heterogeneity and raise the possibility of monogenic inheritance.


Subject(s)
Glomerulonephritis, IGA/genetics , Adolescent , Adult , Biopsy , Disease Progression , Female , Glomerulonephritis, IGA/epidemiology , Humans , Ireland/epidemiology , Kidney Failure, Chronic/epidemiology , Kidney Failure, Chronic/genetics , Kidney Transplantation/statistics & numerical data , Male , Middle Aged , Pedigree , Retrospective Studies , Sex Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...